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ABSTRACT During the human papillomavirus 16 (HPV16) life cycle, the E2 protein
interacts with host factors to regulate viral transcription, replication, and genome
segregation/retention. Our understanding of host partner proteins and their roles
in E2 functions remains incomplete. Here we demonstrate that CK2 phosphoryla-
tion of E2 on serine 23 promotes interaction with TopBP1 in vitro and in vivo and
that E2 is phosphorylated on this residue during the HPV16 life cycle. We investi-
gated the consequences of mutating serine 23 on E2 functions. E2-S23A (E2 with
serine 23 mutated to alanine) activates and represses transcription identically to
E2-WT (wild-type E2), and E2-S23A is as efficient as E2-WT in transient replication
assays. However, E2-S23A has compromised interaction with mitotic chromatin
compared with E2-WT. In E2-WT cells, both E2 and TopBP1 levels increase during mi-
tosis compared with vector control cells. In E2-S23A cells, neither E2 nor TopBP1 levels
increase during mitosis. Introduction of the S23A mutation into the HPV16 genome
resulted in delayed immortalization of human foreskin keratinocytes (HFK) and higher
episomal viral genome copy number in resulting established HFK. Remarkably, S23A
cells had a disrupted viral life cycle in organotypic raft cultures, with a loss of E2
expression and a failure of viral replication. Overall, our results demonstrate that CK2
phosphorylation of E2 on serine 23 promotes interaction with TopBP1 and that this
interaction is critical for the viral life cycle.
IMPORTANCE Human papillomaviruses are causative agents in around 5% of all can-
cers, with no specific antiviral therapeutics available for treating infections or result-
ant cancers. In this report, we demonstrate that phosphorylation of HPV16 E2 by
CK2 promotes formation of a complex with the cellular protein TopBP1 in vitro and
in vivo. This complex results in stabilization of E2 during mitosis. We demonstrate
that CK2 phosphorylates E2 on serine 23 in vivo and that CK2 inhibitors disrupt the
E2-TopBP1 complex. Mutation of E2 serine 23 to alanine disrupts the HPV16 life
cycle, hindering immortalization and disrupting the viral life cycle, demonstrating a
critical function for this residue.
KEYWORDS human papillomavirus, E2, TopBP1, BRD4, cervical cancer, head and neck
cancer, life cycle, CK2, phosphorylation, assay, papillomavirus
Citation Prabhakar AT, James CD, Das D, Otoa
R, Day M, Burgner J, Fontan CT, Wang X, Glass
SH, Wieland A, Donaldson MM, Bristol ML, Li R,
Oliver AW, Pearl LH, Smith BO, Morgan IM.
2021. CK2 phosphorylation of human
papillomavirus 16 E2 on serine 23 promotes
interaction with TopBP1 and is critical for E2
interaction with mitotic chromatin and the
viral life cycle. mBio 12:e01163-21. https://doi
.org/10.1128/mBio.01163-21.
Editor Laimonis A. Laimins, Northwestern
University
Copyright © 2021 Prabhakar et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Iain M. Morgan,
immorgan@vcu.edu.
Received 17 July 2021
Accepted 19 August 2021
Published
















































Human papillomavirus (HPV) infection leads to around 5% of all human cancers,with HPV16 infection being responsible for 50% of cervical cancers and 80 to 90%
of HPV-positive oropharyngeal cancers (1). The latter disease has increased dramati-
cally in the last generation and represents an ongoing public health crisis with no spe-
cific antiviral therapeutics available for combating the disease (2–6). Identification of
such therapeutics is a priority, and our lab focuses on enhancing the molecular under-
standing of the HPV16 life cycle in order to identify potential antiviral targets.
HPVs infect basal epithelial cells, and following cell division, the viral DNA locates to the
cell nucleus (7). The viral genome then replicates to 20 to 50 copies per cell, and the
infected cell begins to proliferate, promoted by the expression of E6 and E7 that target
p53 and pRb (among other proteins), respectively (8, 9). During proliferation, the viral ge-
nome copy number is maintained at around 20 to 50 copies per cell, and in the upper
layers of the epithelium, there is a replication amplification stage where the viral genome
copy number increases. The viral structural proteins L1 and L2 are then expressed and en-
capsulate the viral DNA to form viral particles that egress from the upper layers of the epi-
thelium (10–12).
Throughout the viral life cycle, there are two viral proteins that mediate replication
of the viral genome, E1 and E2 (13–15). E2 is a DNA binding factor whose carboxyl-ter-
minal domain forms homodimers that bind to three 12-bp palindromic DNA sequences
surrounding the viral origin of replication in the long control region (LCR), adjacent to
the transcriptional start site (16, 17). There is a fourth E2 target site in the LCR further
upstream from the viral origin of replication. Following binding to its target sequences,
E2 recruits the viral helicase E1 to the origin of replication via a protein-protein interac-
tion (14–16). At the A/T-rich origin, E1 forms a dihexameric helicase complex that inter-
acts with host DNA polymerases to initiate viral DNA replication (18–21). Furthermore,
E2 has additional roles during the viral life cycle. E2 can regulate transcription from the
viral genome and can either activate or repress transcription depending upon the E2
concentration (22). E2 also regulates transcription from the host genome, and this reg-
ulation is directly relevant to the viral life cycle (23, 24). The fourth function for E2 dur-
ing the viral life cycle is to mediate viral genome segregation (25). During cell division,
the 8-kbp episomal viral genome could be excluded from the nuclei of resulting
daughter cells. To combat this, the virus has an active mechanism that retains viral
genomes in daughter nuclei via hitchhiking onto the host chromatin during mitosis
(25). E2 mediates this function by binding to the viral DNA via its carboxyl-terminal
DNA binding domain and simultaneously binding to host chromatin via the E2 amino-
terminal domain (25). For bovine papillomavirus 1 (BPV1) E2, the host receptor media-
ting interaction with mitotic chromatin is BRD4 (26–29). For high-risk HPV (HR-HPV)
(those that cause cancer, including HPV16), the E2 proteins do not colocalize with
BRD4 on mitotic chromatin, indicating that BRD4 may not be the mitotic receptor for
these E2 proteins (16, 30, 31). We identified TopBP1 as a functional interacting partner
for HPV16 E2 (32–36). TopBP1 regulates the interaction of E2 with host chromatin in
interphase cells and colocalizes with TopBP1 on mitotic chromatin, indicating that
TopBP1 is a candidate protein for mediating E2 interaction with mitotic chromatin (37).
TopBP1 is a multifunctional protein involved in several aspects of nucleic acid me-
tabolism (38). It is part of the replication complex in mammalian cells, interacting with
Treslin to promote the initiation of replication (39–43). TopBP1 contains nine BRCT
(BRCA1 carboxyl-terminal) domains that act as hydrophobic pockets mediating interac-
tion with cellular proteins, including proteins that are phosphorylated following cell
signaling events and are involved in replication initiation and the DNA damage
response (DDR) (44–65). TopBP1 is required for the activation of the ATR (ataxia-telan-
giectasia and Rad3-related) kinase via interaction with ATRIP (ATR-interacting protein),
and TopBP1 is also a substrate for ATM (ataxia-telangiectasia mutated). Both ATM and
ATR are activated during the viral life cycle in order to promote viral genome replica-
tion; therefore, TopBP1 is an essential mediator of the HPV16 life cycle (66–70). TopBP1
also has several roles during mitosis as it prevents transmission of DNA damage
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(including DNA double-strand breaks and catenated DNA) to G1 daughter cells (45, 47,
65, 71–74).
Our previous work identified a mutant of E2 that had a compromised interaction
with TopBP1, asparagine 89 and glutamic acid 90 of E2 were mutated to tyrosine and
valine, respectively (36). The change in nature from polar and charged to bulkier and
more hydrophobic at the substituted residues disrupted the interaction between
HPV16 E2 and TopBP1 (from now on, E2 will mean HPV16 unless stated otherwise). To
gain a more mechanistic understanding of the E2-TopBP1 interaction and how it is
regulated, we tested potential phosphorylation sites on E2 that mediate TopBP1 inter-
action, as TopBP1 binds a number of phosphorylated proteins via its BRCT domains
(38). Here we demonstrate that CK2 phosphorylation of E2 serine 23 promotes the
interaction between E2 and TopBP1 in vitro and in vivo. E2-S23A (an alanine substitu-
tion at position serine 23 which is defective in TopBP1 interaction) and E2-WT (wild-
type E2) have similar transcription and replication functions in our transient assays. E2
recruits TopBP1 onto mitotic chromatin and results in increased expression of both
proteins during this period of the cell cycle, the E2 S23A mutant fails to increase either
TopBP1 or E2 protein levels during mitosis. Introduction of the E2-S23A mutation into
the HPV16 genome results in a delay in human foreskin keratinocyte (HFK) immortal-
ization compared with the wild-type genome. Organotypic raft cultures demonstrate
disruption of the HPV16 life cycle due to mutation of serine 23. Our results demon-
strate a critical role for CK2 phosphorylation of E2-S23 that is important for TopBP1
interaction and mitotic chromatin interaction. Together, our studies suggest that the
E2-TopBP1 interaction is critical at multiple points of the HPV16 life cycle.
RESULTS
E2 serine 23 is critical for TopBP1 interaction in vivo. Because TopBP1 binds to
phosphorylated proteins, we investigated the ability of potential phosphorylation sites
on E2 to mediate the interaction with TopBP1. E2 protein sequence analysis showed
that serine 23 is highly conserved in alpha-type HPV (that incorporate high-risk HPV
[HR-HPV]) (Fig. 1A). Also, on the crystal structure model for HPV16 E2, serine 23 juxta-
poses with amino acids 89 and 90, mutation of which disrupts E2-TopBP1 interaction
(36, 75). To investigate the interaction between E2 and TopBP1 via serine 23, U2OS
cells stably expressing E2-WT (wild-type), E2-S23A (serine mutated to alanine), and E2-
S23D (serine mutated to aspartic acid) were generated, along with pcDNA empty vec-
tor plasmid control (Fig. 1B). Cell extracts from Fig. 1B were immunoprecipitated by a
TopBP1 antibody, and TopBP1 and E2 were detected using Western blotting (Fig. 1C);
this experiment was repeated on three independent extracts and quantitated (Fig. 1D).
While E2-WT and E2-S23D coprecipitate with TopBP1 (Fig. 2C, lanes 4 and 5), E2-S23A
is significantly compromised in this interaction (Fig. 1C, lane 3, and Fig. 1D).
CK2 phosphorylation of E2 promotes interaction with TopBP1 in vitro and in
vivo. The negative charges at positions 21 and 23 in the E2 consensus sequence
around serine 23 (Fig. 1A) indicate a potential CK2 target site at serine 23 (76). CK2 is
also active during mitosis and could therefore be involved in mediating the plasmid
retention function of E2 (77). CK2 interacts with E2, and TopBP1 interacts with CK2
phosphorylated proteins; therefore, we investigated whether CK2 phosphorylates E2
serine 23 (59, 78–80). We prepared recombinant GST-TopBP1 (full length), His-E2-WT,
and His-E2-S23D (amino acids 1 to 200 for both E2 proteins) from bacteria. These pro-
teins were incubated together, and glutathione S-transferase (GST) pulldown experi-
ments were carried out followed by Western blotting (Fig. 2A). Lanes 5 and 6 in Fig. 2A
demonstrate equivalent levels of E2-S23D and E2-WT input in the GST interactions.
Lane 1 demonstrates an interaction between E2-S23D and GST-TopBP1, while lane 2
demonstrates that E2-WT does not interact with TopBP1. Neither protein interacts with
the GST-NEDD4 control protein. This experiment was repeated, and the results were
quantitated (see Fig. S1A in the supplemental material). To determine whether CK2
phosphorylation of E2-WT can promote interaction with TopBP1, we incubated the
recombinant proteins with CK2 enzyme prior to the GST pulldown experiments
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(Fig. 2B). Lane 1 in Fig. 2B demonstrates that the presence of an enzymatically active
CK2 promotes interaction between E2-WT and TopBP1. Omission of CK2 cofactors
(MgCl2/ATP) (lane 2) or CK2 enzyme (lane 3) abolished the interaction. CK2 did not pro-
mote interaction with GST-NEDD4 (present in lanes 5 to 7). This experiment was
repeated, and the results were quantitated (Fig. S1B). To confirm that it is CK2 phos-
phorylation promoting the interaction between E2-WT and TopBP1, we repeated the
experiment in Fig. 2B in the presence of lambda phosphatase which eliminates the
interaction between E2 and TopBP1 (Fig. 2C, lane 2). This experiment was repeated,
and the results were quantitated (Fig. S1C). Unfortunately, we were unable to produce
recombinant E2 S23A protein, despite repeated tries and confirmation that appropriate
RNA was being produced in the bacteria following induction.
To investigate whether E2 S23 is phosphorylated in vivo by CK2, we generated an anti-
body specific for phosphorylated serine 23 (pS23-Ab) using a phospho-peptide incorpo-
rating the region around S23 with the serine phosphorylated (CKILTHYENDSPTDLR). To
investigate whether CK2 was responsible for phosphorylating serine 23 in vivo, we
knocked down CK2 components using small interfering RNA (siRNA). Figure 3A demon-
strates that expression of CK2a and CK2a9 was downregulated using siRNA (lanes 2 and
3, respectively); both were also targeted (lane 4). Nonspecific scrambled control siRNA
(Scr) was used as a control for siRNA treatment in U2OS-Vec and U2OS-E2-WT (lanes 1
and 5, respectively). When both siRNAs were combined, there was a partial knockdown of
both proteins. There was visible toxicity in the double knockdown cells, and the partial
knockdown is likely due to a survival advantage of cells exhibiting a lower degree of both
CK2 component knockdown. Following immunoprecipitation with pS23-Ab, there is
coimmunoprecipitation (co-IP) of E2 in the Scr-treated U2OS-E2-WT cells (lane 5, lower
blot). Under all conditions when CK2 components are targeted by specific siRNAs, there is
an abrogation of detectable E2 co-IP with the pS23-Ab (lanes 2 to 4). To confirm the role
of CK2 in phosphorylating E2 S23 to promote interaction with TopBP1, we used the CK2
FIG 1 (A) Motif analysis of the E2 serine 23 residue region in all a-HPV (top) and high-risk (HR)
(cancer causing) HPV (bottom). (B) Western blots of U2OS cells expressing the indicated E2 proteins.
Vec, vector. (C) Immunoprecipitation with HA (control) and TopBP1 antibody followed by Western
blotting for TopBP1 and E2. (D) Quantitation of repeat TopBP1 co-IPs. E2-specific antibody TVG261
(ab17185) was used for Western blotting in panels B and C. The asterisk indicates a significant
decrease in E2-S23A interaction with TopBP1 compared with E2-WT (P value , 0.05).
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inhibitor CX4945 (Fig. 3B). In the presence of CX4945 (lanes 3 and 4), the interaction
between E2 and TopBP1 is disrupted, and pS23-Ab fails to co-IP E2. To confirm that
knockdown of CK2 components disrupts the E2-TopBP1 interaction, we carried out
TopBP1 co-IPs following CK2a or CK2a9 siRNA knockdown. Figure 3C (lanes 2 and 6 are
blank) demonstrates that knockdown of CK2a reduces the interaction between E2 and
TopBP1. There is knockdown of CK2a expression with the targeting siRNA, while Scr
(scrambled) control has robust CK2a expression (compare lane 4 with lanes 1 and 3). The
hemagglutinin (HA) control antibody IP does not immunoprecipitate TopBP1 or E2 (lane
5), while TopBP1 antibody pulls down both proteins (lanes 7 and 8). There is a reduced
co-IP of E2 with the TopBP1 antibody when CK2a is knocked down (compare lane 7 with
lane 8). This experiment was repeated and quantitated, and there is a statistically signifi-
cant reduction in the interaction between TopBP1 and E2 following knockdown of CK2a
expression (Fig. S2A). Figure 3D demonstrates that knockdown of CK2a9 expression also
reduces the E2-TopBP1 interaction. Lane 3 (taken from the same gel as lanes 1 and 2
with lanes removed) demonstrates a reduction of CK2a9 with targeting siRNA com-
pared with the control Scr siRNA. Immunoprecipitation with TopBP1 antibody results
FIG 2 (A) GST-TopBP1 or GST-NEDD4 (0.65 pmol) was incubated with 11 pmol E2 and incubated at
4°C for 1 h with rotation. GST pulldowns followed by Western blotting for TopBP1 (top blot) and E2
(bottom blot) were then carried out. (B) The GST pulldown was repeated as in panel A following 1 h
at 30°C with CK2 and controls. (C) Lambda phosphatase was added to the CK2 reaction mixture, and
GST pulldown assays were carried out as in panel A. E2-specific antibody TVG261 (ab17185) was used
for Western blotting in all three experiments (A to C). Figure S1A to S1C in the supplemental material
summarizes quantitation of repeat experiments. In the input lanes, only E2 was added. The TopBP1
pulldown demonstrates equivalent levels of TopBP1 in each reaction mixture containing TopBP1.
E2-TopBP1 Interaction Is Essential for the HPV16 Life Cycle ®














































FIG 3 (A) siRNA knockdown of CK2a and/or CK2a9. Scr control siRNA was used in lanes 1 and 5. The top panels
demonstrate the input proteins that were used in the immunoprecipitation (IP) with pS23-Ab (an antibody raised
against an E2 peptide containing a phosphorylated serine 23). Please note the CK2a blot is independent of the
other inputs but is run with the same protein extracts. The IP was blotted for E2 which is clearly detected in the
Scr control (lane 5), but not in the CK2 knockdown cells (lanes 2 to 4). (B) The indicated cells were treated with
DMSO (lanes 1 and 2) or the CK2 inhibitor CX4945 (lanes 3 and 4), and Western blotting details the levels of
TopBP1 and E2 in the treated cells (top blots). Immunoprecipitation (IP) with TopBP1 demonstrates a pulldown of
TopBP1 and E2 (lane 2) that is abrogated by CX4945 (lane 4) (middle blots). IP with pS23-Ab pulled down E2 in
control cells (lane 2) that was abolished by CX4945 (lane 4). (C) CK2a siRNA knockdown (lane 4) disrupted the E2-
TopBP1 interaction as there was a reduced co-IP of E2 in the absence of CK2a (lane 7). (D) CK2a9 knockdown
(lane 3) disrupted the E2-TopBP1 interaction as there was a reduced co-IP of E2 in the absence of CK2a9 (lane 5).
Please note that lanes 1 to 3 are from the same gel and the same exposure with a lane removed. (E) Staining of
U2OS E2-WT (top panels) and U2OS E2-S23A (bottom panels) with pS23-Ab. Left-hand panels are antibody only,
right-hand panels are antibody plus DAPI. There was no signal generated with secondary antibody only, and no
signal detected in U2OS-Vec control when the primary antibody was included. HPV16 E2 B9 monoclonal antibody
was used for Western blotting in panels A and B. E2-specific antibody TVG261 (ab17185) was used for Western
blotting in panels C and D. Figure S2A and S2B summarizes quantitation for repeat experiments of panels C and
D, respectively. An asterisk indicates an antibody band.
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in a co-IP with E2 (lanes 5 and 6). As with CK2a, there is a reduction in the amount of
E2 co-IP with TopBP1 when CK2a9 is knocked down (compare lane 5 with lane 6).
These experiments were repeated and quantitated, and there is a statistically signifi-
cant reduction in the interaction between TopBP1 and E2 following knockdown of
CK2a9 expression (Fig. S2B). The E2-TopBP1 interaction is not completely eliminated
because CK2a and CK2a9 likely compensate for the absence of the other.
To investigate whether E2 is phosphorylated on serine 23 during mitosis, we pre-
pared mitotically enriched U2OS E2-WT and E2-S23A cells. Figure 3E demonstrates a
strong signal in the E2-WT mitotic and interphase cells following pS23-Ab staining.
With E2-S23A cells, staining with pS23-Ab generates no visible staining in interphase
cells, and a very marginal signal in mitotic cells. Figure 5 clearly shows that the E2-
S23A protein is detectable by immunofluorescence in these cells with a non-phospho-
specific E2 antibody, and Fig. 1B demonstrates equivalent expression levels of E2-WT
and E2-S23A in U2OS cells. Overall, Fig. 2 and 3 demonstrate that CK2 phosphorylates
E2 on serine 23 to promote interaction with TopBP1.
CK2 phosphorylates E2 serine 23 in human keratinocytes. We extended our
studies into human keratinocytes, the natural target cell type for HPV16 infection. We
established N/Tert-1 (human foreskin keratinocytes immortalized by human telomer-
ase reverse transcriptase [hTERT]) cells expressing E2-WT and E2-S23A, as described
previously, along with pcDNA Vec control (24). Figure 4A demonstrates expression of
E2-WT and E2-S23A in the N/Tert-1 cells (compare lanes 2 and 3, respectively, with lane
1). Immunoprecipitation brought down TopBP1 in all lines (lanes 4 to 6, top blot), but
only E2-WT interacted strongly with TopBP1, demonstrating that the E2-S23A mutation
also disrupted the E2-TopBP1 interaction in N/Tert-1 cells (compare lane 6 with lane 5).
Figure 4B demonstrates that the pS23-Ab recognizes E2-WT in N/Tert-1 cells; IP with
pS23-Ab pulls down E2 (lane 2). The addition of CX4945 (the CK2 inhibitor) to the N/
Tert-1 cells abolished E2-WT pulldown with pS23-Ab (compare lane 5 with lane 2),
demonstrating that CK2 is responsible for the phosphorylation of E2 serine 23 in N/
Tert-1 cells. Abrogation of E2 serine phosphorylation by CX4945 disrupted the E2-
TopBP1 interaction (Fig. 4C; the inputs from Fig. 4B were used). TopBP1 pulled down
both E2-WT and E2-S23D (as it does in U2OS cells [Fig. 1]) (Fig. 4C, lanes 2 and 3).
Treatment with CX4945 disrupted the interaction between TopBP1 and E2-WT but had
no effect on the interaction with TopBP1 interaction with E2-S23D. Overall, these
results demonstrate that the E2-TopBP1 interaction in N/Tert-1 cells is mediated by
CK2 phosphorylation of serine 23 in N/Tert-1 cells.
To investigate whether E2 S23 is phosphorylated during the HPV16 life cycle, we
stained N/Tert-1 and N/Tert-11HPV16 organotypic raft cultures with the pS23-Ab. Our
previous work demonstrates that N/Tert-11HPV16 cells have episomal HPV16
genomes and support late stages of the HPV16 life cycle (24, 81). Figure 4D demon-
strates that E2 is phosphorylated on serine 23 in the N/Tert-11HPV16 cells (bottom
panels). The N/Tert-1-Vec cells serve as an isogenic control line; there is no positive sig-
nal generated with the pS23-Ab in these cells (top panels). Staining in N/Tert-
11HPV16 is detected throughout the epithelial layer and is clearly nuclear in many of
the cells. Please note that the staining outside of nuclei likely relates to nuclear break-
down in the upper layers of the differentiated epithelium, and also potentially reflect
“smear” artifacts introduced during microsectioning. There is positive staining that is
nuclear in many of the cells in N/Tert-11HPV16. CK2a staining revealed nuclear
expression of this protein in N/Tert-1 and N/Tert-11HPV16, although there appeared
to be less protein detected in the latter, indicating that HPV16 may control the expres-
sion of this protein during the viral life cycle (Fig. 4E).
The E2 S23A mutation disrupts E2 interaction with mitotic chromatin. E2 has
three clear roles in the viral life cycle: regulation of transcription from the viral and
host genomes, replication of the viral genome in association with E1, and segregation
of the viral genome into daughter cells where it acts as a bridge between the viral and
host genomes during mitosis. The latter function guarantees that the viral genomes
are retained in daughter nuclei following mitosis. We measured the transcriptional
E2-TopBP1 Interaction Is Essential for the HPV16 Life Cycle ®














































activation potential of E2-WT and E2-S23A using our ptk6E2-luc system, a plasmid with
six E2 sites located upstream from the herpes simplex virus 1 (HSV-1) thymidine kinase
(tk) promoter driving expression of luciferase (luc) (82, 83). Both E2-WT and E2-S23A
were able to activate transcription from this reporter with no significant difference in
activity (Fig. S3A). E2 can repress transcription from the HPV16 long control region
(LCR), and E2-WT and E2-S23A were equally able to repress transcription from our
pHPV16-LCR-luc reporter (84) (Fig. S3B). Using our transient E1-E2 DNA replication
assay, we demonstrated that both E2-WT and E2-S23A were able to activate replication
with no significant difference between them (85) (Fig. S3C). In support of this, E2-S23A
was able to interact with E1 similarly to E2-WT (Fig. S4).
We next investigated the role of TopBP1 in E2 interaction with mitotic chromatin.
U2OS cells have excellent nuclear architecture and also support HPV replication and
the maintenance of episomal genomes (86). We synchronized the U2OS cells to enrich
for mitotic cells, and Fig. 5A shows representative images from cells stained with 49,69-
FIG 4 (A) Top blots with lanes 1 to 3 are Western blots of extracts from the indicated stable N/Tert-1 cell lines. Bottom blots with
lanes 4 to 6 are Western blots of a TopBP1 immunoprecipitation (IP) of the indicated extracts. TopBP1 co-IPs E2-WT but not E2-
S23A. (B) The extracts in the top blots (Input) were immunoprecipitated with pS23-Ab, and E2 is pulled down by this antibody
(bottom blot, lane 2). The CK2 inhibitor CX4945 abrogates this pulldown (lane 5). (C) The extracts from panel B were
immunoprecipitated with TopBP1, and both E2-WT and E2-S23D co-IP with TopBP1 (lanes 2 and 3). Treatment with the CX4945
abrogates the interaction between TopBP1 and E2-WT (lane 6), but not E2-S23D (lane 5). (D) Organotypic raft cultures of N/Tert-1
(top panels) and N/Tert-11HPV16 (bottom panels) were stained with pS23-Ab. There is no specific staining in N/Tert-1 cells, but
there is clear staining in N/Tert-11HPV16. (Left panels) pS23-Ab only, (right panels) pS23-Ab plus DAPI staining. An asterisk
indicates an antibody band. (E) Organotypic raft cultures of N/Tert-1 (top panels) and N/Tert-11HPV16 (bottom panels) stained
with CK2 antibody. HPV16 E2 B9 monoclonal antibody was used for Western blotting in panels A to C.
Prabhakar et al. ®














































diamidino-2-phenylindole (DAPI), E2, and TopBP1. In the absence of E2, TopBP1 does
not coat mitotic chromatin, instead showing punctate staining associated with the mi-
totic DNA, as observed previously (45) (Fig. 5A, top panels). E2-WT and TopBP1 (middle
panels) colocalized on mitotic chromatin, demonstrating that the presence of E2 pro-
motes TopBP1 interaction with the mitotic chromatin. The mutant E2-S23A localized to
mitotic chromatin along with TopBP1, but the observed staining was less intense. This
pattern of staining was similar in all mitotic cells from the three cell lines. The less intense
staining of mitotic chromatin with E2-S23A, compared with E2-WT, suggests that the
interaction between E2 and TopBP1 may elevate E2 protein levels during mitosis. To
investigate this, U2OS cells were synchronized by double thymidine blocking, and pro-
tein was harvested from the cells every 2 h up until 12 h following release from blocking.
Western blotting was then performed on protein extracts from the cell (Fig. 5B). Flow
FIG 5 (A) U2OS-Vec (top panels), E2-WT (middle panels), and E2-S23A were stained with TopBP1 or
E2 as indicated. In the right-hand panels, a merge of the two antibodies with DAPI staining is shown.
TopBP1 does not specifically associate with mitotic chromatin in the Vec cells, but it does in the E2-
WT and E2-S23A cells. The staining seemed more intense for E2 and TopBP1 with E2-WT than with
E2-S23A. These are representative images from experiments where similar phenotypes are repeatedly
observed in all three lines. (B) The indicated U2OS lines were double thymidine blocked to
coordinate them in G1. They were then released at the indicated time points, and protein extracts
were harvested and Western blotting was carried out. At the 8-h time point, there is an enrichment
for cells in mitosis in all cell lines (Fig. S5A to S5C). These results were repeated and quantitated, and
there was a significant increase of E2 and TopBP1 at the 8-h time point only in U2OS E2-WT cells
(Fig. S5D). E2-specific antibody TVG261 (ab17185) was used for immunofluorescence staining in panel
A and Western blotting in panel B.
E2-TopBP1 Interaction Is Essential for the HPV16 Life Cycle ®














































cytometry of the cell lines demonstrating their cell cycle status at different time
points are shown in Fig. S5A to C. This experiment was repeated and the results for
E2 and TopBP1 quantitated (Fig. S5D). Strikingly, there was a significant increase in
E2 and TopBP1 levels 8 h following release in the E2-WT cells, but no increase of ei-
ther E2 or TopBP1 in E2-S23A or Vec control cells. The 8-h time point correlates
strongly with mitosis (Fig. S5). Overall, the results demonstrate that a major role for
the E2-TopBP1 interaction is to promote increased levels of both proteins during
mitosis. It is also clear that there are other factors that can regulate the interaction
of E2 with chromatin, as E2-S23A still interacts with mitotic chromatin, and TopBP1
is also recruited to mitotic chromatin with E2-S23A. One potential host protein
mediating this function is BRD4, and we demonstrate that BRD4 is able to interact
with E2-S23A and that TopBP1 and BRD4 exist in the same cellular complex
(Fig. S6).
E2 serine 23 and the HPV16 life cycle. To investigate the role of serine 23 during
the HPV16 life cycle, we generated HPV16 genomes containing the E2 S23A and
S23D mutations (HPV16-WT, HPV16-S23A, and HPV16-S23D). We transfected these
genomes into three independent human foreskin keratinocyte (HFK) primary cell cul-
tures to generate immortalized cell lines for life cycle studies. On the first attempt at
immortalization, two out of three donors transfected with HPV16-WT and HPV16-
S23D generated successful, immortalized cell lines, whereas none of the donors were
successfully immortalized by the HPV16-S23A variant (not shown). In the second
attempt, we optimized our immortalization procedure by including feeder cells dur-
ing transfection and selection. Again, we got a striking phenotype with HFK1HPV16-
S23A: all three keratinocyte cultures exhibited an attenuated initial immortalization,
with slow growing colonies. Figure 6A shows an example for one of the HFK cultures
2 weeks following selection, crystal violet staining reveals the reduction in colony for-
mation with HPV16-S23A compared with HPV16-WT and HPV16-S23D. Crystal violet
staining following establishment was carried out in duplicate for all three lines, and
the results are summarized in Fig. 6B.
Even though initial immortalization was attenuated, HFK1HPV16-S23A cells eventu-
ally grew out successfully. Their growth rate was no different from HFK1HPV16-WT or
HFK1HPV16-S23D (Fig. S7). To determine the status of the HPV16 genomes in the cells
(episomal or integrated), Southern blot analysis was carried out (Fig. 6C). In all of the
HPV16 lines, SphI (top blot) (cuts the HPV16 genome once) generated an 8-kbp signal.
Lane 3 contained DNA from N/Tert-1 cells and generated no signal. A band of around
10 kbp was observed in HFK1HPV16-S23D-3. A HindIII (bottom blot) (does not cut the
HPV16 genome) digest generated a slowly migrating species in all samples, indicative
of open circular DNA. Cell lines from all three donors containing HPV16-S23A samples
exhibit significantly faster migrating bands compared with cells containing WT and
S23D genomes (compare lanes 7 to 9 with the others). A striking feature of the SphI
digest is that there is more DNA present in the HFK lines containing the S23A variant
compared with the WT (compare lanes 7 to 9 with lanes 4 to 6). The signals generated
in the HPV16 lines were quantitated relative to the 50 copy number (lane 2) in the SphI
digest. Figure 6D summarizes the quantitation; there is a statistically significant
increase in HPV16 genome copy number in the S23A samples compared to the WT.
These HFK lines represent pools; therefore, there could be increased integration
events in some of the lines compared with others. If there were a general level of
increased integration, DNA would be integrated in millions of different sites and
would not generate detectable signals on Southern blots. We used a recently devel-
oped technique that uses exonuclease-resistant DNA as a measure of episomal status
to determine whether mutation of E2 S23 alters the episomal/integrated status of the
HPV16 genomes (87–89). In this assay, DNA is treated with TV exonuclease (Exo)
which degrades linear DNA, but not circular. We used glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as our linear standard and designated the change in the
threshold cycle (dCt) between samples plus and minus ExoV as 100% degradation.
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We then took the dCt for a mitochondrial marker (a circular genome) and E2 and E6
and determined the percentage of degradation by comparing the dCt difference
with that of GAPDH. The data shown are a summary of the three cell lines gener-
ated (Fig. 6E). The circular mitochondrial DNA is around 90% resistant in all sam-
ples. E2 and E6 are between approximately 50 and 80% resistant. Table S1 in the
FIG 6 (A) Human foreskin keratinocytes (HFK) were transfected with the indicated HPV16 genomes, and
cell colonies formed 2 weeks after transfection and selection with G418 (pcDNA3 G418-resistant plasmid
colonies did not grow out, nor did nontransfected controls). There was a clear reduction in colony size
in three independent HFK donors transfected with HPV16-S23A. This was quantitated, and the results
are shown in panel B. The asterisk indicates a significant reduction in colony size for E2-S23A (P
value , 0.05). (C) DNA extracted from the indicated cell lines were probed with the HPV16 genome in
Southern blots. The top panel demonstrates the presence of 8-kbp bands in all samples following
digestion with the HPV16 genome single cutter SphI. In the bottom panel, results with HindIII, which
does not cut the HPV16 genome, are shown. In all cases, there is a higher-molecular-weight band that
runs similarly to the control DNA (lane 2). (D) The bands in the top panel of panel C (SphI cut) were
quantitated and are summarized here. The asterisk indicates a significant increase in HPV16-S23A
genome copy number (P value , 0.05). (E) To investigate the episomal status of the HPV16 genomes in
all cell lines, we used the TV exonuclease assay (see text for details). There was no significant difference
in the episomal status of the HPV16 genomes between E2-WT, E2-S23A, or E2-S23D. Table S1 in the
supplemental material details the results. Following establishment, the growth rates of the HFK1HPV16-
WT, HFK1HPV16-S23A, and HFK1HPV16 S23D in monolayer cell culture were similar (Fig. S7).
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supplemental material summarizes the results from these assays. Interestingly,
HFK1HPV16-S23D-C is predominantly integrated, and the additional band on the
Southern blot (Fig. 6C, lane 12) may be related to this. What is clear from this experi-
ment is that there is not a significant difference between HFK1HPV16-WT and
HFK1HPV16-S23A/S23D with regards to the episomal status of the viral genomes.
Therefore, the introduction of these mutations does not promote integration of the vi-
ral genome into that of the host. To confirm that our assay robustly differentiates
between episomal and integrated HPV16 genomes, we used W12 clone 20863 (which
contains episomal HPV16 genomes) and W12 clone 20861 (which contains integrated
HPV16 genomes). These clones were generated in the lab of Paul Lambert from the
original cell line established from an HPV16-positive cervical lesion (90, 91).
Figure S8A demonstrates that the HPV16 genome is degraded by TV exonuclease in
clone 20861, but not in clone 20863, confirming the ability of this assay to differenti-
ate between episomal and integrated HPV16 genomes.
While the growth of the cells was not different when grown on plastic, this does
not represent a physiologically relevant part of the HPV16 life cycle. To investigate
whether mutation of serine 23 disrupted the HPV16 life cycle, in addition to attenuat-
ing initial immortalization, we carried out organotypic raft cultures, as we have
described previously (92, 93). Figure 7A gives a representative image from hematoxylin
and eosin (H&E) staining of the organotypic rafts from donor A containing the wild-
type (WT) HPV16 and HPV16 S23A genomes (Fig. 6). There is clearly a “thinner” epithe-
lium with the HPV16 S23A genome containing cells. This is quantitated in Fig. 7B for
two of the three HFK clones; the results are based on duplicate organotypic rafts for
each donor. In addition, there appeared to be an increase in koilocytes with the mutant
genomes (highlighted by the white arrows in Fig. 7A), and quantitation demonstrated
this to be the case (Fig. 7C). Koilocytes are indicative of a more transformed cell, and in
addition to these cells, we also observed a significant increase in whorls with the S23A
mutant cells (see Fig. S8B for an example, and Fig. 7D for a quantitation). These whorls
are found in HPV lesions (94), and HPV-positive ano-genital cancers and head and neck
cancers (95, 96). In addition to the increased number of whorls in the S23A cells, we
also observed several patches where the epithelial layer invades into the stromal colla-
gen plug (Fig. 7E); this was never observed with the wild-type HPV16-containing cells.
The increased koilocytes, whorls, and invasive nature of the S23A cells prompted us
to next investigate the differentiation status of the wild-type and S23A organotypic
rafts. Figure 8A and B demonstrate keratin 10 and involucrin staining, respectively.
Strikingly, the pattern of staining for both differentiation markers is different in the
S23A cells compared with wild-type cells. Keratin 10 staining started “higher” in the ep-
ithelium in the S23A cells, while there are large patches of the S23A samples where
there is an absence of involucrin staining reaching the upper layers of the epithelium.
Both of these results suggest that the S23A cells are not differentiating correctly com-
pared with the wild-type cells. To investigate the proliferative nature of the cells, we
stained with cyclin E (Fig. 8C). Strikingly, there are many more cyclin E-positive cells in
the upper layers of the S23A raft compared with the wild-type counterpart and more
cyclin E positivity overall. This was quantitated in two independent rafts from two inde-
pendent donors, and statistically significantly different levels of cyclin E2 were
observed in the S23A cells (Fig. 8D).
The results in Fig. 7 and 8 demonstrate an aberrant epithelium with the S23A cells
compared with the wild type. We next investigated markers of the viral life cycle.
Figure 9A demonstrates a lack of gH2AX staining in the S23A tissues that was statisti-
cally significantly reduced in two independent donor samples (Fig. 9B). gH2AX is a
marker of viral replication in organotypic raft cultures, as viral replication induces repli-
cation stress and activates the DNA damage response (69, 97). The results therefore
suggested that there was a failure of viral replication in the S23A cells, and to further
investigate this, we carried out FISH staining with labeled HPV16 genome to determine
the levels of viral DNA in the rafts (Fig. 9C). Agreeing with the gH2AX staining, there is
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a loss of viral genomes in the S23A samples as the cells migrate upwards through the
epithelium. This was statistically significant in two independent donors (Fig. 9D). The
loss of staining indicates that the viral genome is likely not being replicated; therefore,
the viral genomes are being “diluted” as the cells proliferate and differentiate. Even in
the basal layers, it is noticeable that there is less signal with the S23A samples com-
pared to the wild-type cells. There is more viral DNA in the S23A cells when they are
grown on plastic (Fig. 6C and D); therefore, the results suggest that there is an immedi-
ate failure to replicate the viral genome upon interaction of the cells with the stromal
collagen/fibroblast plug. Upon seeding onto the collagen plugs, the cells divide several
times before they are induced to differentiate, indicating that the S23A cells are not
replicating viral DNA. Given that the E2-TopBP1 interaction stabilizes the E2 protein
during mitosis (Fig. 5), we investigate the expression of E2 in the S23A and wild-type
rafts (Fig. 9E; this is representative of two independent donor lines). There is clear
FIG 7 (A) Samples A and B from Fig. 6 were subjected to organotypic raft cultures, and H&E staining
was carried out. The white arrows on the S23A panel point to koilocyte-like cells. (B) Duplicate rafts
from two independent samples were scanned for their “height” using the Keyence imaging system,
and the average height for each duplicate is shown. (C) The number of koilocytes in duplicate rafts
from two independent samples was determined using the Keyence imaging system, and average
numbers are shown. (D) The number of whorls observed in rafts from WT and S23A samples was
determined in 10 independent images from each sample. The total number of whorls per raft was
then determined. The asterisks in panels B to D indicate a P value of less than 0.05 for the difference
between the WT and S23A samples. (E) Invasive keratinocytes were observed only in the S23A
samples; an example is highlighted by a white arrow.
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nuclear E2 staining detectable in the wild-type cells throughout the epithelium. In the
upper layers of the epithelium, there is an apparent increase in E2 staining intensity.
However, with the S23A sample, there is a loss of E2 nuclear staining, although there is
a background signal due to nonspecific interaction with the keratin (that has been
“stripped” from the wild-type sample during processing). Therefore, there may be
some residual E2 expression in the S23A sample, but it is dramatically reduced.
DISCUSSION
Here we demonstrate that CK2 phosphorylation of E2 serine 23 results in complex
formation with TopBP1 in vitro and in vivo. The conservation of serine 23 across a-HPV
types (Fig. 1), and the negative aspartic and glutamic acid residues at positions21 and
23, respectively, indicate a potential CK2 target residue (76). In vivo, mutation of S23
to alanine disrupts the coimmunoprecipitation of E2 with TopBP1, while an aspartic
acid mutation (giving a negative charge mimicking phosphorylation) retains interac-
tion (Fig. 1). To demonstrate phosphorylation of S23 in vivo, we generated a phospho-
specific antibody (pS23-Ab) which recognizes E2-WT, including during mitosis, but not
E2-S23A (Fig. 3). CK2 functions as a tetramer with two b-subunits and two a- or
a9-subunits, the latter being the enzymatic components of the complex (76). In Fig. 3,
knockdown of either a component, or partial knockdown of both, abolished detecta-
ble levels of E2 S23 phosphorylation in U2OS cells and partially disrupted the interac-
tion between E2 and TopBP1. The reason for the complete loss of phosphorylation,
and only a partial loss of interaction, could be due to the failure to detect residual E2
phosphorylation following knockdown of the CK2 components. Unfortunately, pS23-
Ab did not work on Western blots; it is possible the antibody recognizes only native E2
and not the denatured versions generated for Western blotting. Another result sup-
porting the important role for CK2 in the phosphorylation of S23 in U2OS cells is that
addition of the CK2 inhibitor CX4945 abolished detectable phosphorylation on this
FIG 8 (A to C) Organotypic raft cultures were stained with the indicated antibodies (left panels), and right
panels show a merge with DAPI for each of the antibodies. (D) A quantitation of cyclin E staining from two
independent rafts of each donor sample. An asterisk indicates a P value of less than 0.05 for the difference
between the WT and S23A samples.
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residue (as determined by pS23-Ab immunoprecipitation) and also disrupted the E2-
TopBP1 interaction (Fig. 3). We extended our studies to demonstrate that S23 is critical
for the E2-TopBP1 interaction in N/Tert-1 cells and that CX4945 abolishes detectable
phosphorylation of E2 on this residue and blocks the E2-TopBP1 interaction in N/Tert-1
cells. We also observed detectable E2 S23 phosphorylation during the HPV16 life cycle
in N/Tert-1 cells (Fig. 4). CK2 was expressed in HPV16-positive cells but was reduced
compared with control cells indicating that HPV16 perhaps regulates CK2 levels during
the differentiation process (Fig. 4E).
As well as demonstrating that CK2 phosphorylation of S23 mediates the E2-TopBP1
interaction in vivo, we also demonstrated that CK2 controls this interaction in vitro
(Fig. 2). E2-WT cannot interact with TopBP1 in vitro, while E2-S23D can. Incubation of
E2-WT with CK2 promotes the interaction between E2 and TopBP1 recombinant pro-
teins, and this can be reversed by treatment with lambda phosphatase. As E2 has been
shown to interact with CK2 components (78), the latter treatment is important, as it
demonstrates that the enzymatic function of CK2 is required to promote the E2-TopBP1
interaction and that it does not act as a “bridge” to bring the two proteins together. The
FIG 9 (A) gH2AX staining of the indicated rafts. The left-hand panels are antibody only; the right-
hand panels are merged with DAPI. There is likely some autofluorescence with the keratin layers in
the differentiated epithelium that are nonspecific. (B) A quantitation of the total gH2AX staining,
determined using the Keyence imager system. (C) Fluorescent in situ hybridization (FISH) staining of
the indicated rafts with a labeled HPV16 genome. Left-hand panels are FISH only, right-hand panels
are merged with DAPI. There is a nonspecific interaction of the FISH probe with the keratin layers of
the differentiated epithelium. (D) Quantitation of the DAPI layers for the FISH signal (therefore
excluding the nonspecific interaction with the keratin layer) using the Keyence imager system. An
asterisk in panel B and D indicates a P value of less than 0.05 for the difference between the WT and
S23A samples. (E) E2 staining of the indicated rafts. The left-hand panels are antibody only; the right-
hand panels are merged with DAPI. HPV16 E2 B9 monoclonal antibody was used in Fig. 9E.
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combination of in vivo and in vitro results demonstrates that CK2 phosphorylation of E2
S23 is crucial for E2-TopBP1 complex formation.
Previous studies have identified several TopBP1 domains that interact with phos-
phorylated peptides (80). The region around E2 S23 does not correspond to a consen-
sus sequence for interacting with any of these TopBP1 domains, and indeed, an E2
pS23 peptide does not interact with any of these domains (see Fig. S9 in the supple-
mental material). This indicates that E2 interacts with a yet to be determined domain
of TopBP1. Future studies will identify this domain; it will be interesting to determine
whether E2 has evolved a unique way to interact with TopBP1 that does not disrupt
the ability of TopBP1 to interact with host proteins involved in the DNA damage
response, a process important for the HPV life cycle (69).
Previous studies have implicated CK2 in several aspects of papillomavirus functions.
CK2 phosphorylation of bovine papillomavirus 1 (BPV1) E2 on 301 regulates the stabil-
ity of this protein (98), although this residue is not conserved on HPV16 E2 and both
E2-WT and E2-S23A are expressed at relatively equivalent levels in both U2OS and N/
Tert-1 cells. CK2 can regulate the DNA binding of BPV and HPV E1 proteins and can
control their DNA replication functions (99). CK2 phosphorylates and regulates HPV18
E1 function and is important in the life cycle of HPV18 and -11 (86, 100). CK2a was the
critical component involved in regulating E1, CK2a9 was not involved. CK2 phosphoryl-
ation of BRD4 is important for mediating HPV16 E2 transcription and replication func-
tion, and we and others have demonstrated that a direct interaction between E2 and
BRD4 is required for E2 transcription function (34, 101, 102). As well as regulating E1-E2
functions, CK2 can also regulate the function of E7 proteins. Phosphorylation of a CK2
consensus sequence on E7 is important for E7 degradation of p130 and the promotion
of S phase in differentiated keratinocytes (103), and a HPV18 E7 CK2 target residue is
required for maintaining the transformed phenotype of cervical cancer cells (104).
In transient replication and transcription assays, the E2-S23A function is similar to E2-
WT (Fig. S3). A third major function for E2 in the viral life cycle is to actively associate
with viral and human DNA simultaneously during mitosis; it is proposed that this func-
tion results in segregation of the viral genomes into daughter nuclei following mitosis
(25). E2 has been shown to bind to mitotic chromatin, and previously we demonstrated
costaining of E2 and TopBP1 on mitotic chromatin (37). Therefore, we investigated the
interaction of E2-WT and E2-S23A with mitotic chromatin (Fig. 5). E2-WT showed robust
staining on mitotic chromatin, and in addition, it recruited TopBP1 onto the mitotic chro-
matin. In control cells with no E2, TopBP1 does not “coat” the mitotic chromatin as it
does with E2-WT. Therefore, like BPV1 E2 and BRD4, E2 alters TopBP1 interaction with mi-
totic chromatin (29). For E2-S23A, there was a reproducible reduction in E2 staining on
mitotic chromatin although it was located on the mitotic chromatin, and also recruited
TopBP1 to the mitotic chromatin. Cell cycle analysis demonstrates that E2-WT levels are
increased during mitosis, while E2-S23A levels are not, agreeing with the staining pat-
terns observed. Additionally, E2-WT increases the levels of TopBP1 during mitosis, while
E2-S23A cannot. Therefore, E2-WT and E2-S23A have distinct phenotypes during mitosis.
We propose that there is an additional factor that mediates the interaction of E2-S23A
with mitotic chromatin, and this is under active investigation. BRD4 is clearly a leading
candidate we are focusing on.
Introduction of the S23A mutation into the HPV16 genome resulted in a delay in
immortalization, although the resulting cells that grew out retained episomal viral
genomes (Fig. 6). These cells were grown on plastic with no feeder cells, and the S23A
mutation had no effect on cell proliferation when the cells were grown in this manner.
However, this is not reflective of any aspect of the HPV16 life cycle, and to determine
the effect of the S23A mutation on this process, we submitted cells to organotypic raft-
ing. This resulted in several striking phenotypes, indicating an epithelial-stroma inter-
action that preferentially affects the HPV16 S23A-containing cells; there is a complex
interaction between HPV-infected cells and the stroma (105). Morphologically, the
S23A cells looked more dysplastic than the wild-type cells with a “thinner” epithelium;
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there was an increase in the number of koilocytes and whorls as well as detection of
epithelial invasion into the collagen/fibroblast stroma (Fig. 7). The S23A cells were also
less differentiated and more proliferative than wild-type cells, again supporting the
idea of an aberrant life cycle and increased dysplasia with the S23A mutant genome
cells. We demonstrate that there is a failure of viral replication with the S23A mutant
resulting in a reduction in viral genomes in the mid-to-upper layers of the differenti-
ated raft (Fig. 9A to D). Finally, we demonstrate that there is a dramatic loss of E2
expression in the S23A cells compared with the wild-type cells (Fig. 9E). The dramatic
effects of the S23A mutation during organotypic rafting compared with cells cultured
on plastic could be related to the interaction of the HPV16-positive cells with the colla-
gen/fibroblast stroma and/or to the differentiation status of the cells. We are currently
investigating these possibilities.
TopBP1 is involved in active replication during mitosis (45, 47, 71, 73, 106). A model
to explain the S23A phenotype is that the E2-TopBP1 interaction locates the viral ge-
nome to sites on chromatin that allow replication of the viral genome during mitosis
or to sites that will promote viral replication during the subsequent S phase following
mitosis. Another model is that the E2-TopBP1 interaction is required for the stabiliza-
tion of E2 in the differentiating epithelium and that without E2 the viral genome will
not be replicated. It is also possible that the S23A mutant is somehow promoting inte-
gration of the viral genome into the host due to an aberrant viral replication function
resulting in a loss of E2 expression. We do not favor the latter idea as it appears the vi-
ral genome does get “diluted” during differentiation, suggesting it has not all inte-
grated (see the fluorescent in situ hybridization [FISH] staining in Fig. 9C). However,
integration of a subset of viral genomes with the S23A mutant would potentially
explain the more transformed phenotypes of the S23A cells, as integration is associ-
ated with a more aggressive HPV-positive tumor. The lack of detectable E2 expression
could also disrupt E2 genome segregation during mitosis, which would also result in a
“dilution” of the viral genomes. However, due to the failure to detectgH2AX (as a surro-
gate marker for viral replication), we favor that E2 degradation and a failure to replicate
causes the phenotypes we observe with the S23A genome-containing cells. It is of
course possible that multiple aberrant functions of E2 S23A could contribute to the
aberrant life cycle.
Future work will focus on understanding the mechanism of the aberrant life cycle
promoted by the S23A mutant. This report demonstrates that the E2-TopBP1 interac-
tion is critical for the HPV16 life cycle and that disrupting it could potentially promote
oncogenesis. Therefore, the E2-TopBP1 interaction may act as a “tumor suppressor
complex” to control the oncogenic properties of HPV16. The results presented also
caution against using CK2 inhibitors for the treatment of HPV16 infections. While such
inhibitors would abolish viral production and therefore potentially block viral transmis-
sion, they could also promote the more transformed phenotypes observed with the
S23A genomes. This could therefore promote oncogenic progression of HPV16 lesions.
As the CK2 inhibitor CX4945 is currently in anticancer combination therapy clinical tri-
als, it will be important for future studies to determine whether such inhibitors do pro-
mote HPV-related lesions/cancers in treated individuals (107).
MATERIALS ANDMETHODS
Generation and culture of stable cell lines. Stable cell lines expressing wild-type E2 (E2-WT), E2-
S23A, and E2-S23D, along with pcDNA empty vector plasmid control were established both in U2OS and
N/Tert-1 cell lines as previously described (23, 24). Cell culture was also performed as described in these
publications.
Western blotting. Protein from cell pellets was extracted with 2 pellet volume protein lysis buffer
(0.5% Nonidet P-40, 50 mM Tris [pH 7.8], and 150 mM NaCl) supplemented with protease inhibitor
(Roche Molecular Biochemicals) and phosphatase inhibitor cocktail (Sigma). The cells were lysed for
20 min on ice followed by centrifugation at 18,000 rcf (relative centrifugal force) for 20 min at 4°C.
Protein concentration was estimated colorimetrically using a Bio-Rad protein assay. Fifty micrograms of
protein with equal volume of 4 Laemmli sample buffer (Bio-Rad) was denatured at 95°C for 5 min. The
samples were run on a Novex WedgeWell 4% to 12% Tris-glycine gel (Invitrogen) and transferred onto a
nitrocellulose membrane (Bio-Rad) using the wet-blot method, at 30 V overnight. The membrane was
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blocked with Li-Cor Odyssey blocking buffer (phosphate-buffered saline [PBS]) diluted 1:1 (vol/vol) with
PBS and then incubated with the specified primary antibody in Li-Cor Odyssey blocking buffer (PBS)
diluted 1:1 with PBS. Following this, the membrane was washed with PBS supplemented with 0.1%
Tween 20 (PBS-Tween) and further probed with the Odyssey secondary antibodies (IRDye 680RD goat
anti-rabbit IgG [H1L] [0.1 mg] or IRDye 800CW goat anti-mouse IgG [H1L] [0.1 mg]) in Li-Cor Odyssey
blocking buffer (PBS) diluted 1:1 with PBS at 1:10,000 for 1 h at room temperature. After washing with
PBS-Tween, the membrane was imaged using the Odyssey CLx Imaging System, and ImageJ was used
for quantification. Primary antibodies used for Western blotting studies are as follows: HPV16 E2 (TVG
261) or monoclonal B9 (1:500) (Abcam ab17185 for TVG261 [108] for monoclonal B9), TopBP1 (1:1,000)
(catalog no. A300-111A; Bethyl), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:10,000) (cata-
log no. sc-47724; Santa Cruz), casein kinase IIa (1AD9) (1:500) (catalog no. sc-12738; Santa Cruz), CKII
alpha' antibody (1:1,000) (catalog no. A300-199A; Bethyl).
Immunoprecipitation. Primary antibody of interest or a HA tag antibody (used as a negative con-
trol) was incubated in 250 mg of cell lysate (prepared as described above), made up to a total volume of
500 ml with lysis buffer (0.5% Nonidet P-40, 50 mM Tris [pH 7.8], and 150 mM NaCl), supplemented with
protease inhibitor (Roche Molecular Biochemicals) and phosphatase inhibitor cocktail (Sigma) and
rotated at 4°C overnight. The following day, 40 ml of prewashed protein A beads per sample (Sigma;
equilibrated to lysis buffer as mentioned in the manufacturer’s protocol) was added to the lysate-anti-
body mixture and rotated for another 4 h at 4°C. The samples were gently washed with 500 ml lysis
buffer by centrifugation at 1,000 rcf for 2 to 3 min. This wash was repeated four times. The bead pellet
was resuspended in 4 Laemmli sample buffer (Bio-Rad), heat denatured, and centrifuged at 1,000 rcf
for 2 to 3 min. Proteins were separated using a sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) system and transferred onto a nitrocellulose membrane before probing for the presence
of E2 or TopBP1, as per the Western blotting protocol.
Immunofluorescence and cell synchronization. U2OS cells expressing stable E2-WT, E2-S23A, and
pcDNA empty vector plasmid control were plated on acid-washed, poly-L-lysine-coated coverslips, in a
six-well plate at a density of 2  105 cells/well (5 ml Dulbecco modified Eagle medium [DMEM] plus 10%
fetal bovine serum [FBS] [DMEM-FBS]). After 24 h, the cells were treated with 2 mM thymidine diluted in
the DMEM-FBS for 16 h. This was then washed two times with PBS and recovered in supplemented
DMEM. After 8 h, to block the cells at G1/S phase, a second dose of 2 mM thymidine was added and incu-
bated for 17 h. The cells were then washed twice with PBS and recovered as before for 3 h. The cells
were next treated with nocodazole (100 ng/ml) for 5 h and released for 2 h to enrich for mitotic cells.
Following this, the cells were washed twice with PBS, fixed, and stained as described in reference 34.
The primary antibodies used are as follows: HPV16 E2 (TVG 261) (1:500) (Abcam; ab17185), HPV16 E2 B9
monoclonal antibody (1:500) (108), TopBP1 (1:1,000) (catalog no. A300-111A; Bethyl), pS23-Ab (1:10,000)
(custom generated by GenScript; peptide sequence, CKILTHYENDSPTDLR). The cells were washed and
incubated with secondary antibodies Alexa Fluor 488-labeled goat anti-mouse (catalog no. A-11001;
Thermo Fisher) and Alexa Fluor 594-labeled goat anti-rabbit (catalog no. A-11037; Thermo Fisher)
diluted 1:1,000. The wash step was repeated, and the coverslips were mounted on a glass slide using
Vectashield mounting medium containing 49,69-diamidino-2-phenylindole (DAPI). Images were captured
with a Zeiss LSM700 laser scanning confocal microscope and analyzed using Zen LE software.
Cell synchronization and Western blotting. U2OS cells expressing stable E2-WT, E2-S23A, and
pcDNA empty vector plasmid control were plated at 3  105 density onto 100-mm plates in DMEM
plus 10% FBS. The cells were treated with 2 mM thymidine diluted in the supplemented DMEM for 16 h.
The cells were then washed two times with PBS and recovered in supplemented DMEM. After 8 h, to
block the cells at G1/S phase, a second dose of 2 mM thymidine was added and incubated for 17 h. The
cells were then washed twice with PBS and recovered as before at the following time points: 0 h and 2 h
(G1/S phase), 4 h and 6 h (S phase), 8 h (M1 phase), 10 h (M2 phase), and 12 h (the next G1 phase). The
cell lysate was prepared using the harvested cells at different time points, and immunoblotting was car-
ried out as described above.
Small interfering RNA (siRNA) and segregation assay. U2OS parental cells were plated on 100-mm
plates. The next day, cells were transfected with 10 mM following siRNA. 10 mM MISSION siRNA Universal
Negative Control (catalog no. SIC001; Sigma-Aldrich) was used as a “nontargeting” control in our experi-
ments. Lipofectamine RNAiMAX transfection (catalog no. 13778-100; Invitrogen) protocol was used in the
siRNA knockdown. Forty-eight hours posttransfection, the cells were harvested, and knockdown was con-
firmed by immunoblotting for the protein of interest. CK2a siRNA was GGCUCGAAUGGGUUCAUCUtt
(Sigma-Aldrich). CK2a9 siRNA was CAGUCUGAGGAGCCGCGAGdTdT.
Production of recombinant protein. Amino acids (aa) 1 to 200 of E2-WT and E2-S23A were pro-
duced as a fused protein with His tag, and TopBP1 was produced as a fused protein with a glutathione
S-transferase (GST) tag (GST TopBP1 [aa 32 to 1522] His from Addgene; plasmid 20375). The protein
expression was carried out by picking a single colony of Escherichia coli BL21(DE3) competent (catalog
no. C2527; NEB Inc.) and growing it in LB medium supplemented with 100 mg/ml of selective antibiotics
(kanamycin for His-tagged E2-WT and E2-S23D; ampicillin for GST-tagged TopBP1), grown overnight at
37°C, and shaken at a low speed. This starter culture was then diluted 1:100 in fresh LB medium with
kanamycin. The culture was shaken at 37°C until the optimal density of 0.6 to 0.8 at an optical density at
600 nm (OD600) was achieved. Following this, isopropyl-b-D-thiogalactopyranoside (IPTG) at a final con-
centration of 1 mM was added to the culture, for induction of protein expression, shaking at 16°C over-
night. His-tagged proteins were purified on nickel-nitrilotriacetic acid (Ni-NTA agarose) (catalog no.
30761; Qiagen), and GST-tagged TopBP1 protein was purified on Glutathione Sepharose 4B (catalog no.
17-0756; GE Health Care), according to the batch purification method described in the manufacturer’s
Prabhakar et al. ®














































manual, followed by size exclusion chromatography. The purity of the recombinant protein was con-
firmed by SDS-PAGE analysis.
In vitro GST pulldown assays. Purified recombinant His-tagged E2-WT and E2-S23D protein and
GST-tagged TopBP1 were used for the in vitro pulldown assays. GST-tagged NEDD4 E3 ligase was used
as our GST control. GST-TopBP1 and GST control were kept stable at 0.65 pmol, and 11 pmol of His-E2-
WT and His-E2-S23D was used for the experiment. Glutathione Sepharose 4B (catalog no. 17-0756; GE
Health Care), equilibrated to the GST lysis buffer (50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 0.5 mM EDTA,
0.5 mM EGTA, 0.5% NP-40, 1 mM dithiothreitol [DTT] plus protease inhibitors) was added, and each tube
was placed at 4°C for 1 h with continual end-to-end rotation. The protein-bound GST beads were
washed three times in the GST lysis buffer by centrifugation at 1,000 rcf for 3 min and resuspended in
4 Laemmli sample buffer (Bio-Rad), heat denatured, and centrifuged at 1,000 rcf for 3 min. The super-
natant was gel electrophoresed using an SDS-PAGE system which was later transferred onto a nitrocellu-
lose membrane using wet-blot transfer method. The membrane was probed for the presence of E2 or
TopBP1 as described above.
In vitro kinase assay with or without lambda phosphatase. Immunoprecipitated GST beads were
prepared as mentioned above in the GST pulldown section. After 1 h, the beads were incubated with
1 ml CK2 enzyme and 1 CK2 reaction buffer (catalog no. P6010S; NEB Inc.) supplemented with 200 mM
ATP and 30 mM MgCl2 and rotated for 1 h at 30°C. The beads were then incubated in the presence or ab-
sence of lambda phosphatase (catalog no. sc-200312A; Santa Cruz) as described in the manufacturer’s
protocol. Following this, the beads were washed and analyzed by immunoblotting.
CK2 inhibitor treatment. U2OS and N/Tert-1 cells were plated at a density of 2  105 in a 100-mm
plate. The next day, the cells were treated with 10 mM CK2 inhibitor, CX-4945 (Silmitasertib) from
APExBIO (catalog no. A8330) or 10mM dimethyl sulfoxide (DMSO) for 48 h. The cells were then harvested
and processed for immunoprecipitation with pS23Ab or TopBP1 as described.
Immortalization of human foreskin keratinocytes (HFK). HPV16 mutant genomes (S23A and
S23D) were generated by Genscript. The HPV16 (WT, S23A, S23D) were removed from their parental
plasmid using SphI, and the viral genomes were isolated and then recircularized using T4 ligase (NEB)
and transfected into early passage HFK from three donor backgrounds (Lifeline Technology), alongside a
G418 resistance plasmid, pcDNA. Cells underwent selection in 200 mg/ml G418 (Sigma-Aldrich) for
14 days and were cultured on a layer of J2 3T3 fibroblast feeders (NIH), which had been pretreated with
8 mg/ml mitomycin C (Roche). Throughout the immortalization process, HFK were cultured in Dermalife-
K complete medium (Lifeline Technology). In Fig. 5A, transfected cells were stained with crystal violet
14 days following transfection and selection prior to passaging.
Southern blotting. Total cellular DNA was extracted by proteinase K-sodium dodecyl sulfate diges-
tion followed by a phenol-chloroform extraction method. Five micrograms of total cellular DNA was
digested with either SphI (to linearize the HPV16 genome) or HindIII (which does not cut the HPV16 ge-
nome). All digests included DpnI to ensure that all input DNA was digested and not represented as repli-
cating viral DNA. All restriction enzymes were purchased from NEB and utilized as per manufacturer’s
instructions. Digested DNA was separated by electrophoresis of a 0.8% agarose gel, transferred to a
nitrocellulose membrane, and probed with radiolabeled (32P) HPV16 genome. This was then visualized
by exposure to film for 1 to 24 h. Images were captured from an overnight-exposed phosphor screen by
GE Typhoon 9410 and quantified using ImageJ.
Exonuclease V assay. To examine whether viral genomes were maintained as episomes, we carried
out an exonuclease V assay, as described by Bienkowska-Haba et al. (89), which determines the resist-
ance of HPV16 genomes to exonuclease V. Twenty nanograms of genomic DNA was either treated with
exonuclease V (RecBCD, NEB), in a total volume of 30 ml, or left untreated for 1 h at 37°C followed by
heat inactivation at 95°C for 10 min. Two nanograms of digested/undigested DNA was then quantified
by real-time PCR using a 7500 FAST Applied Biosystems thermocycler with SYBR green PCR Master Mix
(Applied Biosystems) and 100 nM each primer in a 20-ml reaction mixture. Nuclease-free water was used
in place of the template for a negative control. The following cycling conditions were used: 50°C for 2
min, 95°C for 10 min, 40 cycles at 95°C for 15 s, and a dissociation stage of 95°C for 15 s, 60°C for 1
min, 95°C for 15 s, and 60°C for 15 s. Separate PCRs were performed to amplify HPV16 E6 F (forward),
59- TTGCTTTTCGGGATTTATGC-39, and R (reverse), 59-CAGGACACAGTGGCTTTTGA-39; HPV16 E2 F, 59-
TGGAAGTGCAGTTTGATGGA-39, and R, 59-CCGCATGAACTTCCCATACT-39; human mitochondrial DNA F,
59-CAGGAGTAGGAGAGAGGGAGGTAAG-39, and R, 59-TACCCATCATAATCGGAGGCTTTGG-39; and human
GAPDH DNA F, 59-GGAGCGAGATCCCTCCAAAAT-39, and R, 59-GGCTGTTGTCATACTTCTCATGG-39.
Organotypic raft culture. Keratinocytes were differentiated via organotypic raft culture as described
previously (81, 93). Briefly, cells were seeded onto type 1 collagen matrices containing J2 3T3 fibroblast
feeder cells. Cells were then grown to confluence atop the collagen matrices, lifted onto wire grids, and
cultured in cell culture dishes at the air-liquid interface, with medium replacement on alternate days.
Following 13 days of culture, rafted samples were fixed with formaldehyde (4% [vol/vol]) and embedded
in paraffin blocks. Multiple 4-mm sections were cut from each sample. Sections were stained with hema-
toxylin and eosin (H&E), and other sections were prepared for immunofluorescent staining via HIER.
Fixing and embedding services in support of the research project were generated by the VCU Massey
Cancer Center Cancer Mouse Model Shared Resource. Fixed sections were antigen retrieved in citrate
buffer and probed with the following antibodies for immunofluorescence analysis: phospho-gH2AX (1/
500) (9718; Cell Signaling Technology), cyclin E (1/1,000) (sc-247; Santa Cruz Biotechnology), involucrin
(1/1,000) (ab27495; abcam), keratin 10 (1/1,000) (SAB4501656; SigmaAldrich), CK2a (1/1,000) (SC1273).
Cellular DNA was stained with 49,69-diamidino-2-phenylindole (DAPI) (sc-3598; Santa Cruz). Fluorescent
in situ hybridization (FISH) staining for HPV16 genomes was performed using Alexa Fluor 594-labeled
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HPV16 genomes, generated using the Alexa Fluor 594 DNA labeling kit (Thermo Fisher) as per manufac-
turer’s instructions. Microscopy and subsequent image analysis (percent staining and staining intensity)
was performed using the Keyence imaging system, whereby whole stained sections were scanned com-
putationally and the fluorescence intensity was calculated compared to a negative background control
(secondary antibody only) and a positive localization control (DAPI). Intensity was calculated based on
the number of photons at a specific location, thus determining the local concentration of fluorophores
(secondary antibodies). In this way, this is equivalent to measuring densitometry to estimate protein
concentration from Western blots. The same imaging parameters were used for each slide and for each
sample, and two sections from two individually grown rafts were scanned to generate average values.
Immunofluorescence was observed using a Keyence BZ-X800 microscope and analyzed using BZ-X800
Analyzer software (Keyence Corporation of America).
Statistical analysis. All the data are represented as means 6 standard errors (SE). Significance was
determined using a Student’s t test, and standard error was calculated from independent experiments.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, TIF file, 0.1 MB.
FIG S2, TIF file, 0.1 MB.
FIG S3, TIF file, 0.1 MB.
FIG S4, TIF file, 0.1 MB.
FIG S5, TIF file, 0.4 MB.
FIG S6, TIF file, 0.3 MB.
FIG S7, TIF file, 0.1 MB.
FIG S8, TIF file, 1.6 MB.
FIG S9, TIF file, 0.1 MB.
TABLE S1, XLSX file, 0.01 MB.
ACKNOWLEDGMENTS
This work was supported by VCU Philips Institute for Oral Health Research and the
National Cancer Institute-designated Massey Cancer Center grant P30 CA016059
(I.M.M.), Cancer Research UK C6992/A12695 (I.M.M. and B.O.S.), Cancer Research UK
C302/A14532 (M.D., A.W.O., and L.H.P.), and Cancer Research UK C302/A24386 (M.D.,
A.W.O., and L.H.P.). The VCU Massey Cancer Center Cancer Mouse Model Shared
Resource was supported, in part, with funding from NIH-NCI Cancer Center Support
grant P30 CA016059.
We thank Chris Li, VCU Philips Institute for Oral Health Research, for the kind gift of
the GST-NEDD4 control plasmid.
REFERENCES
1. zur Hausen H. 2009. Papillomaviruses in the causation of human cancers—
a brief historical account. Virology 384:260–265. https://doi.org/10.1016/j
.virol.2008.11.046.
2. Taberna M, Mena M, Pavon MA, Alemany L, Gillison ML, Mesia R. 2017.
Human papillomavirus-related oropharyngeal cancer. Ann Oncol 28:
2386–2398. https://doi.org/10.1093/annonc/mdx304.
3. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF,
Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC,
Redmond KP, Gillison ML. 2010. Human papillomavirus and survival of
patients with oropharyngeal cancer. N Engl J Med 363:24–35. https://doi
.org/10.1056/NEJMoa0912217.
4. Gillison ML. 2004. Human papillomavirus-associated head and neck can-
cer is a distinct epidemiologic, clinical, and molecular entity. Semin
Oncol 31:744–754. https://doi.org/10.1053/j.seminoncol.2004.09.011.
5. Gillison ML, Shah KV. 2001. Human papillomavirus-associated head and
neck squamous cell carcinoma: mounting evidence for an etiologic role for
human papillomavirus in a subset of head and neck cancers. Cur Opin
Oncol 13:183–188. https://doi.org/10.1097/00001622-200105000-00009.
6. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L,
Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D.
2000. Evidence for a causal association between human papillomavirus
and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720.
https://doi.org/10.1093/jnci/92.9.709.
7. Campos SK. 2017. Subcellular trafficking of the papillomavirus genome
during initial infection: the remarkable abilities of minor capsid protein
L2. Viruses 9:370. https://doi.org/10.3390/v9120370.
8. Moody CA, Laimins LA. 2010. Human papillomavirus oncoproteins: path-
ways to transformation. Nat Rev Cancer 10:550–560. https://doi.org/10
.1038/nrc2886.
9. Hebner CM, Laimins LA. 2006. Human papillomaviruses: basic mecha-
nisms of pathogenesis and oncogenicity. Rev Med Virol 16:83–97.
https://doi.org/10.1002/rmv.488.
10. Hong S, Laimins LA. 2013. Regulation of the life cycle of HPVs by differen-
tiation and the DNA damage response. Future Microbiol 8:1547–1557.
https://doi.org/10.2217/fmb.13.127.
11. Schiffman M, Doorbar J, Wentzensen N, de Sanjose S, Fakhry C, Monk BJ,
Stanley MA, Franceschi S. 2016. Carcinogenic human papillomavirus infec-
tion. Nat Rev Dis Primers 2:16086. https://doi.org/10.1038/nrdp.2016.86.
12. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA.
2012. The biology and life-cycle of human papillomaviruses. Vaccine 30
(Suppl 5):F55–F70. https://doi.org/10.1016/j.vaccine.2012.06.083.
13. Kasukawa H, Howley PM, Benson JD. 1998. A fifteen-amino-acid peptide
inhibits human papillomavirus E1-E2 interaction and human papilloma-
virus DNA replication in vitro. J Virol 72:8166–8173. https://doi.org/10
.1128/JVI.72.10.8166-8173.1998.
14. Yasugi T, Benson JD, Sakai H, Vidal M, Howley PM. 1997. Mapping and
characterization of the interaction domains of human papillomavirus
Prabhakar et al. ®














































type 16 E1 and E2 proteins. J Virol 71:891–899. https://doi.org/10.1128/
JVI.71.2.891-899.1997.
15. Benson JD, Howley PM. 1995. Amino-terminal domains of the bovine
papillomavirus type 1 E1 and E2 proteins participate in complex forma-
tion. J Virol 69:4364–4372. https://doi.org/10.1128/JVI.69.7.4364-4372
.1995.
16. Bentley P, Tan MJA, McBride AA, White EA, Howley PM. 2018. The SMC5/
6 complex interacts with the papillomavirus E2 protein and influences
maintenance of viral episomal DNA. J Virol 92:e00356-18. https://doi
.org/10.1128/JVI.00356-18.
17. McBride AA. 2013. The papillomavirus E2 proteins. Virology 445:57–79.
https://doi.org/10.1016/j.virol.2013.06.006.
18. Masterson PJ, Stanley MA, Lewis AP, Romanos MA. 1998. A C-terminal
helicase domain of the human papillomavirus E1 protein binds E2 and
the DNA polymerase alpha-primase p68 subunit. J Virol 72:7407–7419.
https://doi.org/10.1128/JVI.72.9.7407-7419.1998.
19. Loo YM, Melendy T. 2004. Recruitment of replication protein A by the
papillomavirus E1 protein and modulation by single-stranded DNA. J
Virol 78:1605–1615. https://doi.org/10.1128/jvi.78.4.1605-1615.2004.
20. Han Y, Loo YM, Militello KT, Melendy T. 1999. Interactions of the papova-
virus DNA replication initiator proteins, bovine papillomavirus type 1 E1
and simian virus 40 large T antigen, with human replication protein A. J
Virol 73:4899–4907. https://doi.org/10.1128/JVI.73.6.4899-4907.1999.
21. Melendy T, Sedman J, Stenlund A. 1995. Cellular factors required for pap-
illomavirus DNA replication. J Virol 69:7857–7867. https://doi.org/10
.1128/JVI.69.12.7857-7867.1995.
22. Bouvard V, Storey A, Pim D, Banks L. 1994. Characterization of the human
papillomavirus E2 protein: evidence of trans-activation and trans-repres-
sion in cervical keratinocytes. EMBO J 13:5451–5459. https://doi.org/10
.1002/j.1460-2075.1994.tb06880.x.
23. Gauson EJ, Windle B, Donaldson MM, Caffarel MM, Dornan ES, Coleman N,
Herzyk P, Henderson SC, Wang X, Morgan IM. 2014. Regulation of human
genome expression and RNA splicing by human papillomavirus 16 E2 pro-
tein. Virology 468-470:10–18. https://doi.org/10.1016/j.virol.2014.07.022.
24. Evans MR, James CD, Bristol ML, Nulton TJ, Wang X, Kaur N, White EA,
Windle B, Morgan IM. 2019. Human papillomavirus 16 E2 regulates kera-
tinocyte gene expression relevant to cancer and the viral life cycle. J Virol
93:e01941-18. https://doi.org/10.1128/JVI.01067-19.
25. McBride AA, Sakakibara N, Stepp WH, Jang MK. 2012. Hitchhiking on
host chromatin: how papillomaviruses persist. Biochim Biophys Acta
1819:820–825. https://doi.org/10.1016/j.bbagrm.2012.01.011.
26. You J, Croyle JL, Nishimura A, Ozato K, Howley PM. 2004. Interaction of
the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to
host mitotic chromosomes. Cell 117:349–360. https://doi.org/10.1016/
s0092-8674(04)00402-7.
27. Oliveira JG, Colf LA, McBride AA. 2006. Variations in the association of
papillomavirus E2 proteins with mitotic chromosomes. Proc Natl Acad
Sci U S A 103:1047–1052. https://doi.org/10.1073/pnas.0507624103.
28. Brannon AR, Maresca JA, Boeke JD, Basrai MA, McBride AA. 2005. Recon-
stitution of papillomavirus E2-mediated plasmid maintenance in Saccha-
romyces cerevisiae by the Brd4 bromodomain protein. Proc Natl Acad
Sci U S A 102:2998–3003. https://doi.org/10.1073/pnas.0407818102.
29. McPhillips MG, Ozato K, McBride AA. 2005. Interaction of bovine papillo-
mavirus E2 protein with Brd4 stabilizes its association with chromatin. J
Virol 79:8920–8932. https://doi.org/10.1128/JVI.79.14.8920-8932.2005.
30. McBride AA, Oliveira JG, McPhillips MG. 2006. Partitioning viral genomes
in mitosis: same idea, different targets. Cell Cycle 5:1499–1502. https://
doi.org/10.4161/cc.5.14.3094.
31. McPhillips MG, Oliveira JG, Spindler JE, Mitra R, McBride AA. 2006. Brd4 is
required for E2-mediated transcriptional activation but not genome par-
titioning of all papillomaviruses. J Virol 80:9530–9543. https://doi.org/10
.1128/JVI.01105-06.
32. Boner W, Taylor ER, Tsirimonaki E, Yamane K, Campo MS, Morgan IM.
2002. A functional interaction between the human papillomavirus 16
transcription/replication factor E2 and the DNA damage response pro-
tein TopBP1. J Biol Chem 277:22297–22303. https://doi.org/10.1074/jbc
.M202163200.
33. Boner W, Morgan IM. 2002. Novel cellular interacting partners of the
human papillomavirus 16 transcription/replication factor E2. Virus Res
90:113–118. https://doi.org/10.1016/s0168-1702(02)00145-4.
34. Gauson EJ, Donaldson MM, Dornan ES, Wang X, Bristol M, Bodily JM,
Morgan IM. 2015. Evidence supporting a role for TopBP1 and Brd4 in the
initiation but not continuation of human papillomavirus 16 E1/E2
mediated DNA replication. J Virol 89:4980–4991. https://doi.org/10
.1128/JVI.00335-15.
35. Kanginakudru S, DeSmet M, Thomas Y, Morgan IM, Androphy EJ. 2015.
Levels of the E2 interacting protein TopBP1 modulate papillomavirus
maintenance stage replication. Virology 478:129–135. https://doi.org/10
.1016/j.virol.2015.01.011.
36. Donaldson MM, Mackintosh LJ, Bodily JM, Dornan ES, Laimins LA,
Morgan IM. 2012. An interaction between human papillomavirus 16 E2
and TopBP1 is required for optimum viral DNA replication and episomal
genome establishment. J Virol 86:12806–12815. https://doi.org/10.1128/
JVI.01002-12.
37. Donaldson MM, Boner W, Morgan IM. 2007. TopBP1 regulates human
papillomavirus type 16 E2 interaction with chromatin. J Virol 81:
4338–4342. https://doi.org/10.1128/JVI.02353-06.
38. Wardlaw CP, Carr AM, Oliver AW. 2014. TopBP1: a BRCT-scaffold protein
functioning in multiple cellular pathways. DNA Repair (Amst) 22:165–174.
https://doi.org/10.1016/j.dnarep.2014.06.004.
39. Sansam CG, Goins D, Siefert JC, Clowdus EA, Sansam CL. 2015. Cyclin-de-
pendent kinase regulates the length of S phase through TICRR/TRESLIN
phosphorylation. Genes Dev 29:555–566. https://doi.org/10.1101/gad
.246827.114.
40. Boos D, Yekezare M, Diffley JF. 2013. Identification of a heteromeric com-
plex that promotes DNA replication origin firing in human cells. Science
340:981–984. https://doi.org/10.1126/science.1237448.
41. Boos D, Sanchez-Pulido L, Rappas M, Pearl LH, Oliver AW, Ponting CP,
Diffley JFX. 2011. Regulation of DNA replication through Sld3-Dpb11
interaction is conserved from yeast to humans. Curr Biol 21:1152–1157.
https://doi.org/10.1016/j.cub.2011.05.057.
42. Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG. 2011. Direct reg-
ulation of Treslin by cyclin-dependent kinase is essential for the onset of
DNA replication. J Cell Biol 193:995–1007. https://doi.org/10.1083/jcb
.201102003.
43. Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG. 2010. Treslin col-
laborates with TopBP1 in triggering the initiation of DNA replication.
Cell 140:349–359. https://doi.org/10.1016/j.cell.2009.12.049.
44. Yamane K, Tsuruo T. 1999. Conserved BRCT regions of TopBP1 and of the
tumor suppressor BRCA1 bind strand breaks and termini of DNA. Onco-
gene 18:5194–5203. https://doi.org/10.1038/sj.onc.1202922.
45. Leimbacher PA, Jones SE, Shorrocks AK, de Marco Zompit M, Day M,
Blaauwendraad J, Bundschuh D, Bonham S, Fischer R, Fink D, Kessler BM,
Oliver AW, Pearl LH, Blackford AN, Stucki M. 2019. MDC1 interacts with
TOPBP1 to maintain chromosomal stability during mitosis. Mol Cell 74:
571–583.e8. https://doi.org/10.1016/j.molcel.2019.02.014.
46. Blackford AN, Nieminuszczy J, Schwab RA, Galanty Y, Jackson SP,
Niedzwiedz W. 2015. TopBP1 interacts with BLM to maintain genome
stability but is dispensable for preventing BLM degradation. Mol Cell 57:
1133–1141. https://doi.org/10.1016/j.molcel.2015.02.012.
47. Pedersen RT, Kruse T, Nilsson J, Oestergaard VH, Lisby M. 2015. TopBP1 is
required at mitosis to reduce transmission of DNA damage to G1 daugh-
ter cells. J Cell Biol 210:565–582. https://doi.org/10.1083/jcb.201502107.
48. Liu T, Lin YH, Leng W, Jung SY, Zhang H, Deng M, Evans D, Li Y, Luo K,
Qin B, Qin J, Yuan J, Lou Z. 2014. A divergent role of the SIRT1-TopBP1
axis in regulating metabolic checkpoint and DNA damage checkpoint.
Mol Cell 56:681–695. https://doi.org/10.1016/j.molcel.2014.10.007.
49. Ohashi E, Takeishi Y, Ueda S, Tsurimoto T. 2014. Interaction between
Rad9-Hus1-Rad1 and TopBP1 activates ATR-ATRIP and promotes TopBP1
recruitment to sites of UV-damage. DNA Repair (Amst) 21:1–11. https://
doi.org/10.1016/j.dnarep.2014.05.001.
50. Wang RH, Lahusen TJ, Chen Q, Xu X, Jenkins LM, Leo E, Fu H, Aladjem M,
Pommier Y, Appella E, Deng CX. 2014. SIRT1 deacetylates TopBP1 and
modulates intra-S-phase checkpoint and DNA replication origin firing.
Int J Biol Sci 10:1193–1202. https://doi.org/10.7150/ijbs.11066.
51. Duursma AM, Driscoll R, Elias JE, Cimprich KA. 2013. A role for the MRN
complex in ATR activation via TOPBP1 recruitment. Mol Cell 50:116–122.
https://doi.org/10.1016/j.molcel.2013.03.006.
52. Leung CCY, Sun L, Gong Z, Burkat M, Edwards R, Assmus M, Chen J,
Glover JNM. 2013. Structural insights into recognition of MDC1 by
TopBP1 in DNA replication checkpoint control. Structure 21:1450–1459.
https://doi.org/10.1016/j.str.2013.06.015.
53. Qu M, Rappas M, Wardlaw CP, Garcia V, Ren J-Y, Day M, Carr AM, Oliver
AW, Du L-L, Pearl LH. 2013. Phosphorylation-dependent assembly and
coordination of the DNA damage checkpoint apparatus by Rad4TopBP1.
Mol Cell 51:723–736. https://doi.org/10.1016/j.molcel.2013.08.030.
E2-TopBP1 Interaction Is Essential for the HPV16 Life Cycle ®














































54. Wang J, Chen J, Gong Z. 2013. TopBP1 controls BLM protein level to
maintain genome stability. Mol Cell 52:667–678. https://doi.org/10.1016/
j.molcel.2013.10.012.
55. Leung CCY, Gong Z, Chen J, Glover JNM. 2011. Molecular basis of
BACH1/FANCJ recognition by TopBP1 in DNA replication checkpoint
control. J Biol Chem 286:4292–4301. https://doi.org/10.1074/jbc.M110
.189555.
56. Lindsey-Boltz L, Sancar A. 2011. Tethering DNA damage checkpoint me-
diator proteins topoisomerase IIb-binding protein 1 (TopBP1) and clas-
pin to DNA activates ataxia-telangiectasia mutated and RAD3-related
(ATR) phosphorylation of checkpoint kinase 1 (Chk1). J Biol Chem 286:
19229–19236. https://doi.org/10.1074/jbc.M111.237958.
57. Wang J, Gong Z, Chen J. 2011. MDC1 collaborates with TopBP1 in DNA
replication checkpoint control. J Cell Biol 193:267–273. https://doi.org/
10.1083/jcb.201010026.
58. Balestrini A, Cosentino C, Errico A, Garner E, Costanzo V. 2010. GEMC1 is
a TopBP1-interacting protein required for chromosomal DNA replication.
Nat Cell Biol 12:484–491. https://doi.org/10.1038/ncb2050.
59. Takeishi Y, Ohashi E, Ogawa K, Masai H, Obuse C, Tsurimoto T. 2010. Casein
kinase 2-dependent phosphorylation of human Rad9 mediates the interac-
tion between human Rad9-Hus1-Rad1 complex and TopBP1. Genes Cells
15:761–771. https://doi.org/10.1111/j.1365-2443.2010.01418.x.
60. Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG. 2009.
The Mre11-Rad50-Nbs1 complex mediates activation of TopBP1 by ATM.
Mol Biol Cell 20:2351–2360. https://doi.org/10.1091/mbc.e08-12-1190.
61. Morishima K, Sakamoto S, Kobayashi J, Izumi H, Suda T, Matsumoto Y,
Tauchi H, Ide H, Komatsu K, Matsuura S. 2007. TopBP1 associates with NBS1
and is involved in homologous recombination repair. Biochem Biophys Res
Commun 362:872–879. https://doi.org/10.1016/j.bbrc.2007.08.086.
62. Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG. 2007.
Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR
occurs through phosphorylation of TopBP1 by ATM. J Biol Chem 282:
17501–17506. https://doi.org/10.1074/jbc.M701770200.
63. Kumagai A, Lee J, Yoo HY, Dunphy WG. 2006. TopBP1 activates the
ATR-ATRIP complex. Cell 124:943–955. https://doi.org/10.1016/j.cell
.2005.12.041.
64. Mäkiniemi M, Hillukkala T, Tuusa J, Reini K, Vaara M, Huang D, Pospiech
H, Majuri I, Westerling T, Mäkelä TP, Syväoja JE. 2001. BRCT domain-con-
taining protein TopBP1 functions in DNA replication and damage
response. J Biol Chem 276:30399–30406. https://doi.org/10.1074/jbc
.M102245200.
65. Yamamoto RR, Axton JM, Yamamoto Y, Saunders RD, Glover DM,
Henderson DS. 2000. The Drosophila mus101 gene, which links DNA
repair, replication and condensation of heterochromatin in mitosis, enc-
odes a protein with seven BRCA1 C-terminus domains. Genetics 156:
711–721. https://doi.org/10.1093/genetics/156.2.711.
66. Anacker DC, Moody CA. 2017. Modulation of the DNA damage response
during the life cycle of human papillomaviruses. Virus Res 231:41–49.
https://doi.org/10.1016/j.virusres.2016.11.006.
67. Anacker DC, Aloor HL, Shepard CN, Lenzi GM, Johnson BA, Kim B, Moody
CA. 2016. HPV31 utilizes the ATR-Chk1 pathway to maintain elevated
RRM2 levels and a replication-competent environment in differentiating
keratinocytes. Virology 499:383–396. https://doi.org/10.1016/j.virol.2016
.09.028.
68. Gautam D, Moody CA. 2016. Impact of the DNA damage response on
human papillomavirus chromatin. PLoS Pathog 12:e1005613. https://doi
.org/10.1371/journal.ppat.1005613.
69. Moody CA, Laimins LA. 2009. Human papillomaviruses activate the ATM
DNA damage pathway for viral genome amplification upon differentiation.
PLoS Pathog 5:e1000605. https://doi.org/10.1371/journal.ppat.1000605.
70. Hong S, Cheng S, Iovane A, Laimins LA. 2015. STAT-5 regulates transcrip-
tion of the topoisomerase IIbeta-binding protein 1 (TopBP1) gene to
activate the ATR pathway and promote human papillomavirus replica-
tion. mBio 6:e02006-15. https://doi.org/10.1128/mBio.02006-15.
71. Bagge J, Oestergaard VH, Lisby M. 2021. Functions of TopBP1 in preserv-
ing genome integrity during mitosis. Semin Cell Dev Biol 113:57–64.
https://doi.org/10.1016/j.semcdb.2020.08.009.
72. Broderick R, Nieminuszczy J, Blackford AN, Winczura A, Niedzwiedz W.
2015. TOPBP1 recruits TOP2A to ultra-fine anaphase bridges to aid in
their resolution. Nat Commun 6:6572–6572. https://doi.org/10.1038/
ncomms7572.
73. Germann SM, Schramke V, Pedersen RT, Gallina I, Eckert-Boulet N,
Oestergaard VH, Lisby M. 2014. TopBP1/Dpb11 binds DNA anaphase
bridges to prevent genome instability. J Cell Biol 204:45–59. https://doi
.org/10.1083/jcb.201305157.
74. Bang SW, Ko MJ, Kang S, Kim GS, Kang D, Lee J, Hwang DS. 2011. Human
TopBP1 localization to the mitotic centrosome mediates mitotic progres-
sion. Exp Cell Res 317:994–1004. https://doi.org/10.1016/j.yexcr.2011.01
.022.
75. Antson AA, Burns JE, Moroz OV, Scott DJ, Sanders CM, Bronstein IB,
Dodson GG, Wilson KS, Maitland NJ. 2000. Structure of the intact transac-
tivation domain of the human papillomavirus E2 protein. Nature 403:
805–809. https://doi.org/10.1038/35001638.
76. Nuñez de Villavicencio-Diaz T, Rabalski AJ, Litchfield DW. 2017. Protein
kinase CK2: intricate relationships within regulatory cellular networks.
Pharmaceuticals (Basel) 10:27. https://doi.org/10.3390/ph10010027.
77. Rusin SF, Adamo ME, Kettenbach AN. 2017. Identification of candidate
casein kinase 2 substrates in mitosis by quantitative phosphoproteo-
mics. Front Cell Dev Biol 5:97. https://doi.org/10.3389/fcell.2017.00097.
78. Jang MK, Anderson DE, van Doorslaer K, McBride AA. 2015. A proteomic
approach to discover and compare interacting partners of papillomavi-
rus E2 proteins from diverse phylogenetic groups. Proteomics 15:
2038–2050. https://doi.org/10.1002/pmic.201400613.
79. Bigot N, Day M, Baldock RA, Watts FZ, Oliver AW, Pearl LH. 2019. Phos-
phorylation-mediated interactions with TOPBP1 couple 53BP1 and 9-1-1
to control the G1 DNA damage checkpoint. Elife 8:e44353. https://doi
.org/10.7554/eLife.44353.
80. Day M, Rappas M, Ptasinska K, Boos D, Oliver AW, Pearl LH. 2018. BRCT
domains of the DNA damage checkpoint proteins TOPBP1/Rad4 display
distinct specificities for phosphopeptide ligands. Elife 7:e39979. https://
doi.org/10.7554/eLife.39979.
81. Evans MR, James CD, Loughran O, Nulton TJ, Wang X, Bristol ML, Windle
B, Morgan IM. 2017. An oral keratinocyte life cycle model identifies novel
host genome regulation by human papillomavirus 16 relevant to HPV
positive head and neck cancer. Oncotarget 8:81892–81909. https://doi
.org/10.18632/oncotarget.18328.
82. Vance KW, Campo MS, Morgan IM. 2001. A novel silencer element in the
bovine papillomavirus type 4 promoter represses the transcriptional
response to papillomavirus E2 protein. J Virol 75:2829–2838. https://doi
.org/10.1128/JVI.75.6.2829-2838.2001.
83. Vance KW, Campo MS, Morgan IM. 1999. An enhanced epithelial
response of a papillomavirus promoter to transcriptional activators. J
Biol Chem 274:27839–27844. https://doi.org/10.1074/jbc.274.39.27839.
84. Bristol ML, James CD, Wang X, Fontan CT, Morgan IM. 2020. Estrogen
attenuates the growth of human papillomavirus-positive epithelial cells.
mSphere 5:e00049-20. https://doi.org/10.1128/mSphere.00049-20.
85. Taylor ER, Morgan IM. 2003. A novel technique with enhanced detection
and quantitation of HPV-16 E1- and E2-mediated DNA replication. Virol-
ogy 315:103–109. https://doi.org/10.1016/s0042-6822(03)00588-9.
86. Piirsoo A, Piirsoo M, Kala M, Sankovski E, Lototskaja E, Levin V, Salvi M,
Ustav M. 2019. Activity of CK2a protein kinase is required for efficient
replication of some HPV types. PLoS Pathog 15:e1007788. https://doi
.org/10.1371/journal.ppat.1007788.
87. Myers JE, Zwolinska K, Sapp MJ, Scott RS. 2020. An exonuclease V-qPCR
assay to analyze the state of the human papillomavirus 16 genome in
cell lines and tissues. Curr Protoc Microbiol 59:e119. https://doi.org/10
.1002/cpmc.119.
88. Myers JE, Guidry JT, Scott ML, Zwolinska K, Raikhy G, Prasai K,
Bienkowska-Haba M, Bodily JM, Sapp MJ, Scott RS. 2019. Detecting epi-
somal or integrated human papillomavirus 16 DNA using an exonucle-
ase V-qPCR-based assay. Virology 537:149–156. https://doi.org/10.1016/j
.virol.2019.08.021.
89. Bienkowska-Haba M, Luszczek W, Myers JE, Keiffer TR, DiGiuseppe S,
Polk P, Bodily JM, Scott RS, Sapp M. 2018. A new cell culture model to ge-
netically dissect the complete human papillomavirus life cycle. PLoS
Pathog 14:e1006846. https://doi.org/10.1371/journal.ppat.1006846.
90. Flores ER, Lambert PF. 1997. Evidence for a switch in the mode of human
papillomavirus type 16 DNA replication during the viral life cycle. J Virol
71:7167–7179. https://doi.org/10.1128/JVI.71.10.7167-7179.1997.
91. Stanley MA, Browne HM, Appleby M, Minson AC. 1989. Properties of a
non-tumorigenic human cervical keratinocyte cell line. Int J Cancer 43:
672–676. https://doi.org/10.1002/ijc.2910430422.
92. Das D, Bristol ML, Smith NW, James CD, Wang X, Pichierri P, Morgan IM.
2019. Werner helicase control of human papillomavirus 16 E1-E2 DNA
replication is regulated by SIRT1 deacetylation. mBio 10:e01635-19.
https://doi.org/10.1128/mBio.01635-19.
Prabhakar et al. ®














































93. James CD, Das D, Morgan EL, Otoa R, Macdonald A, Morgan IM. 2020.
Werner syndrome protein (WRN) regulates cell proliferation and the
human papillomavirus 16 life cycle during epithelial differentiation.
mSphere 5:e00858-20. https://doi.org/10.1128/mSphere.00858-20.
94. Jin MS, Lee H, Kim MA, Park IA, Lee C, An HJ, Shim B, Moon JH, Won JK,
Ryu HS. 2018. Novel cytomorphologic characteristics suggesting human
papillomavirus infection in patients diagnosed as negative for intraepi-
thelial lesion or malignancy and a comparison of diagnostic perform-
ance of three human papillomavirus tests. Diagn Cytopathol 46:833–839
. https://doi.org/10.1002/dc.24049.
95. Prat J. 2015. Pathology of cancers of the female genital tract. Int J Gynae-
col Obstet 131(Suppl 2):S132–S145. https://doi.org/10.1016/j.ijgo.2015
.06.010.
96. Dive AM, Bodhade AS, Mishra MS, Upadhyaya N. 2014. Histological pat-
terns of head and neck tumors: an insight to tumor histology. J Oral Max-
illofac Pathol 18:58–68. https://doi.org/10.4103/0973-029X.131912.
97. James CD, Fontan CT, Otoa R, Das D, Prabhakar AT, Wang X, Bristol ML,
Morgan IM. 2020. Human papillomavirus 16 E6 and E7 synergistically
repress innate immune gene transcription. mSphere 5:e00828-19.
https://doi.org/10.1128/mSphere.00828-19.
98. Penrose KJ, Garcia-Alai M, de Prat-Gay G, McBride AA. 2004. Casein ki-
nase II phosphorylation-induced conformational switch triggers degra-
dation of the papillomavirus E2 protein. J Biol Chem 279:22430–22439.
https://doi.org/10.1074/jbc.M314340200.
99. Schuck S, Ruse C, Stenlund A. 2013. CK2 phosphorylation inactivates
DNA binding by the papillomavirus E1 and E2 proteins. J Virol 87:
7668–7679. https://doi.org/10.1128/JVI.00345-13.
100. Piirsoo A, Kala M, Sankovski E, Ustav M, Piirsoo M. 2020. Uncovering the role
of the E1 protein in different stages of human papillomavirus 18 genome
replication. J Virol 94:e00674-20. https://doi.org/10.1128/JVI.00674-20.
101. Wu SY, Nin DS, Lee AY, Simanski S, Kodadek T, Chiang CM. 2016. BRD4
phosphorylation regulates HPV E2-mediated viral transcription, origin
replication, and cellular MMP-9 expression. Cell Rep 16:1733–1748.
https://doi.org/10.1016/j.celrep.2016.07.001.
102. Schweiger MR, You J, Howley PM. 2006. Bromodomain protein 4 medi-
ates the papillomavirus E2 transcriptional activation function. J Virol 80:
4276–4285. https://doi.org/10.1128/JVI.80.9.4276-4285.2006.
103. Genovese NJ, Banerjee NS, Broker TR, Chow LT. 2008. Casein kinase II motif-
dependent phosphorylation of human papillomavirus E7 protein promotes
p130 degradation and S-phase induction in differentiated human keratino-
cytes. J Virol 82:4862–4873. https://doi.org/10.1128/JVI.01202-07.
104. Basukala O, Mittal S, Massimi P, Bestagno M, Banks L. 2019. The HPV-18
E7 CKII phospho acceptor site is required for maintaining the trans-
formed phenotype of cervical tumour-derived cells. PLoS Pathog 15:
e1007769. https://doi.org/10.1371/journal.ppat.1007769.
105. Spurgeon ME, Lambert PF. 2017. Human papillomavirus and the stroma:
bidirectional crosstalk during the virus life cycle and carcinogenesis.
Viruses 9:219. https://doi.org/10.3390/v9080219.
106. Gallina I, Christiansen SK, Pedersen RT, Lisby M, Oestergaard VH. 2016.
TopBP1-mediated DNA processing during mitosis. Cell Cycle 15:176–183.
https://doi.org/10.1080/15384101.2015.1128595.
107. D’Amore C, Borgo C, Sarno S, Salvi M. 2020. Role of CK2 inhibitor CX-4945
in anti-cancer combination therapy 2 potential clinical relevance. Cell
Oncol (Dordr) 43:1003–1016. https://doi.org/10.1007/s13402-020-00566-w.
108. Wieland A, Patel MR, Cardenas MA, Eberhardt CS, Hudson WH, Obeng
RC, Griffith CC, Wang X, Chen ZG, Kissick HT, Saba NF, Ahmed R. 2020.
Defining HPV-specific B cell responses in patients with head and neck
cancer. Nature https://doi.org/10.1038/s41586-020-2931-3.
E2-TopBP1 Interaction Is Essential for the HPV16 Life Cycle ®
September/October 2021 Volume 12 Issue 5 e01163-21 mbio.asm.org 23
D
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//j
ou
rn
al
s.
as
m
.o
rg
/jo
ur
na
l/m
bi
o 
on
 1
1 
O
ct
ob
er
 2
02
1 
by
 1
39
.1
84
.1
56
.3
0.
